Metformin Offers No Survival Boost in Metastatic Prostate Cancer

(MedPage Today) — An antidiabetic mainstay did not provide an additional survival benefit to patients with metastatic hormone-sensitive prostate cancer, according to results from a phase III trial.
In STAMPEDE, overall survival was not statistically…